Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab
B Jessen, Yasmina Rodriguez‐Sillke, Elena Sonnenberg, Michael Schümann, Andrey Kruglov, I Freise, Franziska Schmidt, Jochen Maul, Anja A. Kühl, Rainer Glauben, Donata Lissner, Britta Siegmund
Topics & Concepts
MedicineInfliximabPeripheral blood mononuclear cellTumor necrosis factor alphaInternal medicineInflammatory bowel diseaseGastroenterologyProspective cohort studyCytokineUlcerative colitisClinical endpointCrohn's diseaseC-reactive proteinCalprotectinImmunologyInflammationDiseaseClinical trialBiochemistryIn vitroChemistryInflammatory Bowel DiseaseNeutrophil, Myeloperoxidase and Oxidative MechanismsAutoimmune and Inflammatory Disorders Research